AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06527027 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Lymph node assessment according to RECIST 1.1 in CT
Description: RECIST 1.1 classifies lymph nodes as healthy when they have a short axis dimension (SAD) of \<10 mm; Nodes with a SAD dimension >=10 mm are considered to be involved in the cancer process.
Study NCT06527027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lymph node assessment according to Node-RADS in CT
Description: Node-RADS classifies lymph nodes taking into account parameters such as: size, degree of homogeneity, boundaries and shape of the node. Depending on the degree of change in a given parameter, an appropriate number of points are awarded in each category, and the sum of the points determines the final classification of the node into one of five categories of probability of being affected by a cancer process: 1-very low, 2-low, 3-medium, 4 -high, 5-very high.
Study NCT06527027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lymph node assessment according to LN-RADS in CT
Description: LN-RADS (Lymph Node Reporting and Data System) categorizes nodes according to a scale that reflects the radiological and clinical forms of the nodes and the level of probability of a malignant process:~LN-RADS 1 - normal lymph node LN-RADS 2 - enlarged and fatty lymph node, not suspected from an oncological point of view LN-RADS 3 - lymph node with features suggesting reactive changes. LN-RADS 4a - lymph node with slight oncological suspicion LN-RADS 4b - lymph node with strong oncological suspicion LN-RADS 5 - definitely cancerous node
Study NCT06527027 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Lymph node assessment according to RECIST 1.1 in MRI
Description: RECIST 1.1 classifies lymph nodes as healthy when they have a short axis dimension (SAD) of \<10 mm; Nodes with a SAD dimension >=10 mm are considered to be involved in the cancer process.
Study NCT06527027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lymph node assessment according to Node-RADS in MRI
Description: Node-RADS classifies lymph nodes taking into account parameters such as: size, degree of homogeneity, boundaries and shape of the node. Depending on the degree of change in a given parameter, an appropriate number of points are awarded in each category, and the sum of the points determines the final classification of the node into one of five categories of probability of being affected by a cancer process: 1-very low, 2-low, 3-medium, 4 -high, 5-very high.
Study NCT06527027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lymph node assessment according to LN-RADS in MRI
Description: LN-RADS (Lymph Node Reporting and Data System) categorizes nodes according to a scale that reflects the radiological and clinical forms of the nodes and the level of probability of a malignant process:~LN-RADS 1 - normal lymph node LN-RADS 2 - enlarged and fatty lymph node, not suspected from an oncological point of view LN-RADS 3 - lymph node with features suggesting reactive changes. LN-RADS 4a - lymph node with slight oncological suspicion LN-RADS 4b - lymph node with strong oncological suspicion LN-RADS 5 - definitely cancerous node
Study NCT04647162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematoma evacuation by craniotomy
Description: The intervention method of hematoma evacuation is under craniotomy.
Study NCT04647162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematoma evacuation by stereotactic puncture
Description: The intervention method of hematoma evacuation is under stereotactic puncture.
Study NCT04647162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematoma evacuation by neuroendoscopy
Description: The intervention method of hematoma evacuation is under neuroendoscopy.
Study NCT04647162 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: life support
Description: The treatments in medical group includes life support, nutrition support, and rehabilitation therapy。
Study NCT06530667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: broadband collaborative pulse ablation
Description: Via CT guided, patients with malignant pulmonary nodules would be treated by broadband collaborative pulse ablation
Study NCT05730205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexplanon 68 MG Drug Implant
Description: Progestin contraceptive device
Study NCT04759131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efanesoctocog alfa (BIVV001)
Description: Pharmaceutical form: solution for injection Route of administration: IV
Study NCT05839600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1821736
Description: Solution for infusion
Study NCT06099990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets
Description: dalpiciclib+ abiraterone+ prednisone
Study NCT06099990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo; abiraterone acetate tablets; prednisone tablets
Description: placebo+abirarerone+prenisone
Study NCT05039918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective touch
Description: Gentle stroking at CT-optimal speed
Study NCT05660395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Intravenous (IV) Infusion
Study NCT05701462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: biopsy under sonographic gidance
Description: pleural biopsy under sonographic guidance
Study NCT06016686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VNS stimulation and intraneural recordings
Description: A minimum of three stimulation frequencies (1, 10 and 30 Hz), each up to 60s in duration, will be delivered via the VNS device. Intraneural recordings proximal or distal to the VNS electrodes during delivery of VNS will be performed. Approximately two to five fascicles will be explored in each nerve.
Study NCT06016686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Record multi-unit activity from intraneural sites
Description: Perform a more detailed vagal nerve mapping study by recording from single nerve fibers, including those fibers supplying the heart, lungs, airways and other end-organs. The investigators shall perform functional mapping of the left and right vagus nerves, such as those with cardiac-related and/or respiratory-related neural activity. The research team will also record activity from other nearby fibers to map the differences in neurological behavior in fascicles that control the heart, lungs, airways and other systems.
Study NCT05088720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol 800 µg
Description: received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
Study NCT05088720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol 400 µg
Description: received misoprostol 400 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
Study NCT06041490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multi-kinase inhibitors in combination with bevacizumab
Description: The eligible participants will start taking multi-kinase inhibitors between 4-8 weeks after liver transplantation. The choice of the specific multi-kinase inhibitor, including sorafenib, lenvatinib, or regorafenib, will be determined by the researchers based on factors such as the participant's tumor characteristics, liver function, physical condition, risk of side effects, economic status, and personal preference. The specific dosage and administration details can be found in the table provided. The maximum duration of multi-kinase inhibitor treatment will be 12 months or until any of the following conditions occur, whichever comes first: 1) The participant experiences intolerable toxic reactions that do not alleviate with dose adjustments, or 2) The participant has documented disease recurrence confirmed through imaging or withdraws from the study for other reasons.
Study NCT06185751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WS-CART-CS1
Description: -Subject will be hospitalized for 7 days
Study NCT05118243 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control cracker
Description: The gut symptoms caused by control crackers are studied in IBS persons
Study NCT05118243 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enzyme-treated cracker
Description: The gut symptoms caused by enzyme-treated crackers are studied in IBS persons
Study NCT06303921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-M503 PET
Description: 2 hour Positron Emission Tomography (PET) scan using new radiotracer 11C-M503
Study NCT06303921 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain MRI
Description: MRI scan of brain.
Study NCT04884399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMAB818
Description: vascular endothelial growth factor (VEGF) inhibitor
Study NCT04884399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis®
Description: vascular endothelial growth factor (VEGF) inhibitor
Study NCT05822609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: 1.0 mg
Study NCT05822609 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05165030 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood Sample
Description: clinical-radiological evaluation, genetic analysis by whole exome sequencing and constitution of a bio-collection
Study NCT06018194 — intervention group
Intervention type: DEVICE
Intervention: ElucidVivo
Description: Plaque morphology characterization on coronary CTA for predicting fractional flow reserve (FFRct)
Study NCT06046326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual community of practice
Description: The intervention group will be offered participation for 12 months in a VCoP based ona gamified web-based application.
Study NCT04211766 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Fiber
Description: Given fiber supplement
Study NCT04211766 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Given fish oil supplement
Study NCT04211766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator
Description: Given fiber supplement placebo
Study NCT04211766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator
Description: Given fish oil supplement placebo (corn oil)
Study NCT06185751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepleting chemotherapy
Description: * Cyclophosphamide 500 mg/m\^2 IV on Days -5, -4, and -3~* Fludarabine 30 mg/m\^2 IV on Days -5, -4, and -3
Study NCT06570070 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5A's/5R's advice
Description: 5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
Study NCT06570070 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 5A's/5R's advice
Description: 5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
Study NCT06570070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief leaflet on health warning and smoking cessation
Description: The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.
Study NCT06570070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief leaflet on health warning and smoking cessation
Description: The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.
Study NCT06570070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-help smoking cessation booklet
Description: The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.
Study NCT06570070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-help smoking cessation booklet
Description: The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.
Study NCT06570070 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI-powered chatbot support
Description: Participants will receive three months of AI-powered chatbot, equipped with personalized interactions and real-time support, via WeChat.
Study NCT06570070 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselor individual support
Description: Participants will receive three months of counselor-led individual support via WeChat. The regular messages and instant messaging on psychosocial support aim to provide cessation advice, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.
Study NCT06571617 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini PCNL (mini percutaneous nephrolithotomy)
Description: half of the cases will be treated using mini PCNL
Study NCT06571617 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RIRS (retrograde intrarenal surgery/ flexible URS)
Description: THE OTHER HALF WILL BE TRAETED USING Flexible URS
Study NCT06569732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homemade oral nutrition supplements
Description: The homemade oral nutrition supplement is made of soy milk, whey protein powder, vegetable oil, and fruit juices
Study NCT06569732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercial oral nutrition supplements
Description: The commercial oral nutrition supplement is kidney-specific oral nutrition supplement that is high in energy and protein, but low in electrolytes and fluid
Study NCT06303921 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Amyloid PET
Description: PET scan with Florbetaben F18 or 11C-PiB
Study NCT06303921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurological assessments
Description: Neurological assessments, including a video interview.
Study NCT06157151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGN-2009 plus Pembrolizumab
Description: Subjects randomized will receive PRGN-2009 (5 x 10\^11 PU, subcutaneous (SC) injection) every 3 weeks for three administrations, thereafter subjects will continue to receive PRGN-2009 administrations every 6 weeks. Pembrolizumab will be administered concurrently as intravenous (IV) infusion (400 mg) every 6 weeks.
Study NCT06157151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab alone
Description: Subjects randomized will receive IV infusion of pembrolizumab (400 mg) administered every 6 weeks.
Study NCT04971707 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized exercise training
Description: HRV index will be measured every morning during 5 min. This group will benefit from the standard cardiovascular rehabilitation program combining both continuous moderate exercise sessions (MICT) and high intensity interval exercise sessions (HIIT). MICT sessions will be performed 2 times per week and HIIT sessions will be performed once a week.
Study NCT04971707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HRV-guided exercise training
Description: HRV index will be measured every morning during 5 min. This group will benefit from the individualized cardiovascular rehabilitation program. Daily exercise (MICT, HIIT, or active recovery) will be prescribed according to the HRV-index measured on the morning of the session.
Study NCT04134052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine sedation versus midazolam sedation
Description: Sedation with ketamine 5-20 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% during surgery and the second midazolam group 5 mcg- 35 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% will be administered during surgery
Study NCT04134052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine sedation versus midazolam sedation
Description: Sedation with ketamine 5-20 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% during surgery and the second midazolam group 5 mcg- 35 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% will be administered during surgery
Study NCT05419557 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Family-Based Healthy Plate Club
Description: IHPC provides produce boxes, nutrition and meal-preparation, education, and supportive counseling to address barriers related to obtaining produce and food. The intervention provides participants with a bi-weekly produce box for 12 weeks and helps families identify sustainable ways to obtain vegetables once the produce boxes end. The CHW will support families by coaching them on how to prepare these unfamiliar vegetables, give tips on finding sales at grocery stores, as well as by navigation to food assistance sites including food pantries. Parents will learn strategies to increase vegetable consumption by addressing perceived barriers - such as the child doesn't like vegetables. Curriculum will also include topics such as how to increase physical activity and reduce screen time.
Study NCT06481839 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Starting dose of NE
Description: Patients will be randomized to either low-dose (5mcg/min) or high-dose (15mcg/min) norepinephrine (NE) for their first vasopressor in shock.
Study NCT05192733 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: This is a cross-sectional practice survey. There is no intervention.
Study NCT04727931 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neuropsychological assessement and questionnaires
Description: Neuropsychological assessement including memory, working memory, executive function, oral naming and speed processing tests. There are questionnaires to assess mood disorders, anxiety and cognitive reserve.
Study NCT05352178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy (SBRT) and/or surgery (metastasectomy)
Description: Metastasis-directed therapay (surgery and/or radiotherapy) as treatment for oligorecurrent lesions
Study NCT05352178 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy (SBRT) and/or surgery (metastasectomy)
Description: Metastasis-directed therapay (surgery and/or radiotherapy) as treatment for oligorecurrent lesions
Study NCT05352178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Description: Arm B: gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im Arm C: gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or leuproreline 45 mg sc or triptoreline 3.75 mg im 1x/month or triptoreline 11.5 mg im 1x/3months or triptoreline 22.5 mg im
Study NCT05352178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen receptor targeted therapy
Description: Enzalutamide
Study NCT06203236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide 20 MG
Description: 1. The median daily total dose of intravenous loop diuretic at the start of treatment will be 20 mg of furosemide.~2. Monitoring of urinary sodium excretion (natriuresis) and diuresis will begin 2 hours after treatment initiation.
Study NCT06203236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diuretic therapy
Description: diuretic therapy
Study NCT06293131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: Ciprofol was injected intravenously, and was pumped during operation to maintain sedation
Study NCT05055128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X842
Description: Patients will receive X842 tablets.
Study NCT05055128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: X842 Dummy
Description: Patients will receive matching placebo tablets for X842.
Study NCT05055128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X842 Dummy
Description: Patients will receive matching placebo tablets for X842.
Study NCT05055128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Patients will receive Lansoprazole capsule.
Study NCT04962334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation standardized formula.
Description: Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
Study NCT04962334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Low caloric formula (powder added to water) without added vitamins and minerals